Oct 16, 202614 min
Recent regulatory and clinical developments include the approval of Weltruza — the first once-monthly subcutaneous long-acting formulation of olanzapine for schizophrenia — as well as the first subcutaneous therapy for...
About this Podcast:
Each week the MPR team brings you the top stories from the world of medicine and pharma in a matter of minutes. With 35 years of publishing drug information behind us, you can rely on MPR to provide accurate and up-to-date news.
Pitch Analysis
Required Pod Score for this podcast. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
37%
Guest openness
Selective
80/100
Required Score
Sign up to generate a grounded pitch for MPR Weekly Dose.
Signup to Generate a PitchQuestions about MPR Weekly Dose
What is MPR Weekly Dose about?
Each week the MPR team brings you the top stories from the world of medicine and pharma in a matter of minutes. With 35 years of publishing drug information behind us, you can rely on MPR to provide accurate and up-to-date news.
What has MPR Weekly Dose covered recently?
Recent episodes include "MPR Weekly Dose Podcast #290, Weltruza, Hovilpri Approved, Atezolizuman Regimens for Stage III dMMR Colon CA; Subcutaneous Tx for TED; Vanda’s Anxiety Tx Falls" (16 October 2026, 14 minutes), "MPR Weekly Dose Podcast #289, Juvmo for Parkinson Disease; Camzyos Approval Expanded; MS Treatment Gains Priority Review; Sudden BLA Withdrawal for a Key Lung Cancer Candidate" (2 October 2026, 12 minutes), and "MPR Weekly Dose Podcast #288, CagriSema Weight Loss Results; ALS Treatment Shows Promise; Primary IgA Nephropathy Tx; Gene Therapy Approved for Sanfilippo Syndrome; Lyrfigtu Approved" (25 September 2026, 12 minutes).
How often does MPR Weekly Dose publish?
MPR Weekly Dose publishes roughly weekly, with episodes averaging 13 minutes across 290 episodes.
How hard is it to get booked on MPR Weekly Dose?
Booking probability for MPR Weekly Dose is 37%, and the host is rated Selective on guests. MPR Weekly Dose requires a Pod Score of 80 or higher. MPR Weekly Dose's contact route on record: verified email.
Who should pitch MPR Weekly Dose?
The strongest fits for MPR Weekly Dose are Health & Wellness Services and Scientific Research & Development. MPR Weekly Dose has a health audience.
About the host
MPR Weekly Dose is a health podcast with 290 episodes published.
Verified host email: ████████@████.comSign in to unlock →
Recent episodes
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Oct 2, 202612 minNew FDA approvals for Juvmo in Parkinson disease and Camzyos in pediatric obstructive hypertrophic cardiomyopathy, a Priority Review green light for fenebrutinib in MS, and the sudden BLA withdrawal for a key lung...
Sep 25, 202612 minResults for weight loss treatment combo cagrilintide and semaglutide; positive results for treatment of rare form of ALS, and for sefaxersen in adults with primary IgA nephropathy; gene therapy approved for Sanfilippo...
Sep 18, 202613 minApprovals for spinal muscular atrophy and chronic kidney disease; Joenja gains expanded approval in APDS; LSD derivative earns Breakthrough status to treat major depressive disorder; and zasocitinib is granted Priority...
Sep 11, 202613 minFirst treatment approved for Alexander disease; Hyrnuo and Etcamah are approved for lung cancer and breast cancer, respectively; Pelacarsen misses endpoint in the phase 3 HORIZON trial, and atogepant shows promise from...
View More
Sep 4, 202611 minMounjaro approval expanded to reduce the risk of major cardiovascular events; The American Academy of Pediatrics has issued updated recommendations for RSV immunization; BTK inhibitor shows promise in relapsing MS; and...
- Sep 4, 202611 min
Mounjaro approval expanded to reduce the risk of major cardiovascular events; The American Academy of Pediatrics has issued updated recommendations for RSV immunization; BTK inhibitor shows promise in relapsing MS; and...
Aug 17, 202615 minIn a special episode of the MPR Weekly Dose podcast, Dr William Schaffner — professor of preventive medicine and infectious diseases at Vanderbilt University School of Medicine and former CDC Epidemic Intelligence...
Aug 7, 202612 minModerna's mRNA influenza vaccine gains FDA approval; approvals for prostate cancer, narcolepsy type 1 and Mucinex 12HR; and peanut allergy treatment gains Fast Track status.
Jul 31, 202615 minAn over-the-counter acetaminophen/naproxen sodium fixed-dose tablet gains approval; Simtriyo approved for ADHD; Xocova approved for COVID-19 postexposure prophylaxis; A new contraceptive patch is approved; and Furoscix...
Jul 24, 202615 minKalshi start clinical trials, FDA approvals prediction market; positive results shared for triple hormone therapy retatrutide; Jideytro gains approval in advanced or metastatic ROS1-positive NSCLC; a smart toilet seat...
Jul 17, 202615 minThe latest on the multistate cyclospora outbreak; Lipfendra approved to reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia; subcutaneous starting dose regimen approved for Leqembi; NDA...
Jul 10, 202614 minA new treatment is approved to reduce proteinuria in adults with primary immunoglobulin A nephropahty; a swimmer's ear treatment and the thyroid hormone replacement therapy Amerithroid are now available; Casgevy...
Jun 12, 202613 minA single, once-weekly tablet could change HIV treatment landscape; weight loss drug orforglipron efficacy assessed at all stages of menopause; hemophilia treatment Hympavzi gains expanded indication; and the FDA adds a...
Jun 5, 202612 minNew treatment approved for adults with complicated urinary tract infections; Xocova approved for COVID-19 postexposure prophylaxis; investigational diabetic macular edema eye drop fails to meet trial endpoint; Afrezza...
May 29, 202614 minNew triple hormone receptor agonist shows significant weight loss; hepatitis delta virus treatment gains accelerated approval; acne gel gains OTC designation; constipation treatment expanded to include younger patients...
May 15, 202612 minUS News and World Report releases their annual best over-the-counter products list; new guidance for drug safety evaluation during pregnancy; gMG indication broadened for efgartigimod; Beqalzi gains accelerated approval...
May 8, 202610 minOzempic tablets are now available; investigational ALS treatment gains FDA Fast Track status; positive results for aficamten in non-obstructive hypertrophic cardiomyopathy; motion sickness drug Nereus now available...
May 1, 202614 minGene therapy approved to restore hereditary hearing loss; investigational treatment shows hair coverage improvements in male pattern loss; Breztri approved as a maintenance treatment for asthma; gene editing candidate...
Apr 24, 202612 minTwo-drug, single-tablet approved to replace current antiretroviral regimen; Dupixent approved for pediatric CSU; novel treatment significantly improves survival in metastatic pancreatic cancer; oral semaglutide for...
Recent guests
Recent guests on MPR Weekly Dose. Study who booked and why before you pitch.
C
Charles Raison
Director of Behavioral Health Innovation Center, University of Wisconsin – Madison
P
Preeti Malani
University of Michigan
Best industries to pitch MPR Weekly Dose for
PitchCentric classifies MPR Weekly Dose under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Similar Podcasts
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Podcasts like MPR Weekly Dose
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ